Bristol Myers Hid Zola-Cel Trial Pause for Three Months; ICANS Cases Emerge
BMY sits 60% above its 52-week low of $42.52.
Summary
Bristol Myers paused its Zola-Cel CAR-T program for autoimmune diseases in early June due to life-threatening ICANS (brain inflammation) side effects, but only disclosed the pause this week after a William Blair analyst noticed frozen trials in a database. The company says the cases were transient and reversible with no fatalities, but the three-month delay in public disclosure raises serious transparency concerns. This follows the September 1 Reuters report of the pause, but adds critical new details: the adverse events were ICANS, the pause began in June, and the company did not voluntarily disclose it. The article also reveals that Novartis paused its similar rap-cel therapy after three patient deaths, highlighting a broader safety issue in next-generation CAR-T for autoimmune diseases. Investors should watch for further regulatory scrutiny and potential impact on the company's autoimmune pipeline, which was a key growth driver.
At the time of this announcement, BMY was trading at $68.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $139.1B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.